Pacific Biometrics Names New Business Development Manager.

SEATTLE -- Pacific Biometrics Inc. (OTCBB: PBME; "PBI"), a provider of specialized central laboratory and contract research services, has hired Patrick Jackle as its new Business Development Manager. In this role, Mr. Jackle will help promote and maintain PBI's collaborative and business relationships with diagnostic, pharmaceutical and biotech companies for laboratory services for clinical research nationwide. E[acute accent]Mario Ehlers, MD, PhD, Chief Medical Officer of Pacific Biometrics, commented, "We are very pleased that Patrick has agreed to join the company. Patrick brings extensive experience and knowledge of the pharmaceutical and healthcare industries, a key requirement for successful marketing of PBI's laboratory services in support of clinical drug development. Over the past 12-18 months the company has significantly upgraded its business development and sales and marketing activities. Patrick is a key new hire who we expect will make a major contribution to our efforts to drive sales and grow revenues going forward." E[acute accent]Ehlers continued, "We are very encouraged by our recent successes in signing significant new contracts for specialty testing and with Patrick joining the company we look forward to continued success in winning additional business and expanding our client base." E[acute accent]Mr. Jackle brings to PBI more than 15 years of healthcare sales experience, including management of new-product and new-indication launches. Before joining the Company, Mr. Jackle was District Manager of Novartis Pharmaceuticals, where he facilitated seven promotions, including Elidel and Lamisil, which were first in their respective therapeutic classes. Prior, he also served as District Sales Manager at Columbia Laboratories, Inc., and Northwest Regional Manager of Viva International Group. Mr. Jackle holds a Bachelor of Science degree from California State Polytechnic University.

E[acute accent]About Pacific Biometrics, Inc. (PBI):

E[acute accent]Established in 1989, PBI provides specialized central laboratory and contract research services to support pharmaceutical and diagnostic manufacturers conducting human clinical trial research. The company delivers expert services in the areas of cardiovascular disease, diabetes, osteoporosis, arthritis and nutrition. The PBI laboratory is accredited by the College of American Pathologists and, through its non-profit affiliate Pacific Biometrics Research Foundation, is one of only three U.S.-based members of the Centers for Disease Control (CDC) Cholesterol Reference Method Laboratory Network. PBI's clients include many of the world's largest pharmaceutical, biotech and diagnostic companies. E[acute accent]Pacific Biometrics also owns several patented and patent-pending technologies, including monitoring devices for glucose and changes in bone turnover, an advanced, proprietary, isothermal DNA amplification technology, and a gene-based cell-viability technology to distinguish live from dead cells in a broad range of diagnostic applications. E[acute accent]For more information about Pacific Biometrics, visit the company's Web site at www.pacbio.com.

E[acute accent]Forward-Looking Statements:

E[acute accent]Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This press release includes forward-looking statements including to but not limited to our strategic planning and business development plans, our future growth, and the viability and acceptance of our products and services in the market. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ materially from those described in the forward-looking statements. These risks include, but are not limited to, our ability to bid on and win laboratory services contracts, the success of our marketing and business development efforts, competition in the industry, and our ability to manage growth, as well as the risks and other factors set forth in our periodic filings with the U.S. Securities and Exchange Commission (including our Form 10-KSB for the year ended June 30, 2005 and our reports on Form 10-QSB for the quarters ended September 30, 2005 and December 31, 2005).